Welcome to Bayer Life Talks

The Bayer Life Talks series is designed as a platform for open and public discussion on how innovations in life sciences should play a role in modern economies, and the contribution they can make to overcoming societal challenges. 

The first of the sessions took place on 9 September and focused on gene editing, following the European Commission’s recent study on new genomic techniques. While the second session of 2021 took place 8 December and looked at the fault lines and opportunities in the relationship between policymakers, business, and the scientific community.

Further information on upcoming 2022 events will be made available shortly.

If you are interested in learning more about the series, please contact us here.

Previous Session

The Science of Transparency: Delivering Quality of Life Improvements through Transparent Science & Policymaking

8 December 2021 / Online 15:00 - 16:15

A trusted relationship between science, business, and policymaking is essential for the proper functioning of our democracies. Science and academia play a necessary role in policymaking, offering evidence-based research to guide the formulation and direction of the rules that govern. We are, however, living in a period of increased distrust in traditional institutions, with the organisations and experts that were once valued and relied upon, now subject to growing skepticism.

In the context of the recent strengthening of transparency rules for those seeking to influence policymaking in Europe and following the public consultation on developing a fit for purpose European innovation ecosystem to boost innovation cohesion, this second session in the Bayer Life Talks will look at the fault lines and opportunities in the relationship between policymakers, business, and the scientific community. It will debate the role of business in funding academic and scientific research and what tools are available to ensure transparency and accountability in the process. What guard rails currently exist to ensure that evidence-based policymaking can thrive?

With the European Union undertaking several initiatives to reinforce the ambition and global competitiveness of its European Research Area, and while the demand for insight and future proof policymaking increases, how is the business community working to ensure that it continues to play a positive role in science and research, and what are the implications for the innovation agenda in Europe?

Key Themes


Quality of Life

Global Competitiveness

Session 2 Agenda

All session timings are in CET


Paul Adamson, Chairman, Forum Europe

15:00 - 15:05
Opening Remarks

Stephan Schraff, Head Public Affairs European Union, Bayer AG

15:05 - 15:20
Keynote Presentation

Nicole Grobert, Chair, Group of Chief Scientific Advisors to the European Commission

15:20 - 16:15

Maria da Graça Carvalho, Member, European Parliament

Michael Vorländer, Head of Unit for Education and Research, German Permanent Representation to the EU

David Mair, Head of Unit, Science Advice to Policy, EC Joint Research Centre

Dr Anna-Maija Mertens, Executive Director, Transparency International

Dr. Monika Lessl, SVP, Head Corporate R&D and Social Innovation, Bayer AG

Lidia Borrell-Damián, Secretary-General, Science Europe

Event Close

Speakers have included...

Event Partners

Get in touch

For more information on any aspect of the Bayer Life Talks series, please contact us using the details below:

James Wilmott

Managing Director | Forum Europe

Tel: +44 (0) 7760 160 618

Email: [email protected]